Samantha Prout L.'s most recent trade in Amicus Therapeutics Inc was a trade of 12,240 Common Stock done at an average price of $14.3 . Disclosure was reported to the exchange on Jan. 2, 2026.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Amicus Therapeutics Inc | Samantha L. Prout | Chief Accounting Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 14.27 per share. | 02 Jan 2026 | 12,240 | 125,951 (0%) | 0% | 14.3 | 174,665 | Common Stock |
| Amicus Therapeutics Inc | Samantha L. Prout | Chief Accounting Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 14.27 per share. | 02 Jan 2026 | 3,443 | 138,191 (0%) | 0% | 14.3 | 49,132 | Common Stock |
| Amicus Therapeutics Inc | Samantha L. Prout | Chief Accounting Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Dec 2025 | 32,193 | 141,634 (0%) | 0% | 0 | Common Stock | |
| Amicus Therapeutics Inc | Samantha Prout L. | Chief Accounting Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 11 Feb 2025 | 27,416 | 122,941 (0%) | 0% | 0 | Common Stock | |
| Amicus Therapeutics Inc | Samantha Prout L. | Chief Accounting Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 9.57 per share. | 11 Feb 2025 | 13,500 | 109,441 (0%) | 0% | 9.6 | 129,195 | Common Stock |
| Amicus Therapeutics Inc | Samantha Prout L. | Chief Accounting Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2025 | 62,715 | 62,715 | - | - | Stock Options (right to buy) | |
| Amicus Therapeutics Inc | Samantha Prout L. | Chief Accounting Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2025 | 34,614 | 105,097 (0%) | 0% | 0 | Common Stock | |
| Amicus Therapeutics Inc | Samantha Prout L. | Chief Accounting Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 9.41 per share. | 02 Jan 2025 | 8,275 | 96,822 (0%) | 0% | 9.4 | 77,868 | Common Stock |
| Amicus Therapeutics Inc | Samantha Prout L. | Chief Accounting Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 9.31 per share. | 02 Jan 2025 | 3,443 | 70,483 (0%) | 0% | 9.3 | 32,054 | Common Stock |
| Amicus Therapeutics Inc | Samantha Prout L. | Chief Accounting Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 9.41 per share. | 02 Jan 2025 | 1,297 | 95,525 (0%) | 0% | 9.4 | 12,205 | Common Stock |